OSR Holdings, Inc. operates as a blank check company. The company is headquartered in Bellevue, Washington. The company went IPO on 2023-02-10. The firm is focused on building and developing a portfolio of transformative therapies and healthcare solutions. The firm's operating businesses (through its three wholly owned subsidiaries) include developing oral immunotherapies for the treatment of cancer, developing design-augmented biologics for age-related and other degenerative diseases and neurovascular intervention medical device and systems distribution in Korea. The Company’s subsidiary, Vaximm’s flagship asset, VXM01, is a late clinical-stage (NCT037500701) immuno-oncology candidate for glioblastoma. Vaximm has three clinical and pre-clinical drug candidates targeting diseases ranging from glioblastoma to gastrointestinal stromal tumor to ocular diseases. The firm has operations in Europe and South Korea.
